AK104-201
03 Nov 2020
Trial Summary
A Single-arm, Open-label, Global, Multicenter, Phase 2 Study to Evaluate the Efficacy of AK104 in Patients with Recurrent or Metastatic Cervical Cancer
Acronym:
AK104-201
ACTRN/NCT /ethics:
NCT04380805
Scientific title:
A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer
Sponsor / Cooperative group:
Akeso
Trial & Patient Characteristics
| Cancer Type | Gynaecological |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18+ years |
| Sex | Female |
| Tumour Stream | Cervical |
| Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
| Anticipated Start Date | 2020-07-15 |
| Anticipated End Date | 2022-02-01 |
Participating Hospitals
| Hospital | Ashford Cancer Centre Research |
|---|---|
| Clinical Trial Coordinator | Sue Yeend |
| syeend@adelaidecancercentre.com.au | |
| Phone | 08 8292 2240 |
| Principal Investigator | Dr Meena Okera |
| Recruitment Status | Recruiting |